• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

泛癌分析确定AIMP2为乳腺癌的潜在生物标志物。

Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.

作者信息

Qiu Jie, Zhou Tao, Wang Danhong, Hong Weimin, Qian Da, Meng Xuli, Liu Xiaozhen

机构信息

Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang, China.

General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou 310000, Zhejiang, China.

出版信息

Curr Genomics. 2023 Dec 20;24(5):307-329. doi: 10.2174/0113892029255941231014142050.

DOI:10.2174/0113892029255941231014142050
PMID:38235352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10790333/
Abstract

INTRODUCTION

Aminoacyl tRNA synthetase complex interacting with multifunctional protein 2 (AIMP2) is a significant regulator of cell proliferation and apoptosis. Despite its abnormal expression in various tumor types, the specific functions and effects of AIMP2 on tumor immune cell infiltration, proliferation, and migration remain unclear.

MATERIALS AND METHODS

To assess AIMP2's role in tumor immunity, we conducted a pan-cancer multi-database analysis using the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Lines Encyclopedia (CCLE) datasets, examining expression levels, prognosis, tumor progression, and immune microenvironment. Additionally, we investigated AIMP2's impact on breast cancer (BRCA) proliferation and migration using cell counting kit 8 (CCK-8) assay, transwell assays, and western blot analysis.

RESULTS

Our findings revealed that AIMP2 was overexpressed in 24 tumor tissue types compared to normal tissue and was associated with four tumor stages. Survival analysis indicated that AIMP2 expression was strongly correlated with overall survival (OS) in certain cancer patients, with high AIMP2 expression linked to poorer prognosis in five cancer types.

CONCLUSION

Finally, siRNA-mediated AIMP2 knockdown inhibited BRCA cell proliferation and migration . In conclusion, our pan-cancer analysis suggests that AIMP2 may play a crucial role in tumor immunity and could serve as a potential prognostic marker, particularly in BRCA.

摘要

引言

氨酰tRNA合成酶复合体相互作用多功能蛋白2（AIMP2）是细胞增殖和凋亡的重要调节因子。尽管其在多种肿瘤类型中表达异常，但AIMP2对肿瘤免疫细胞浸润、增殖和迁移的具体功能及影响仍不清楚。

材料与方法

为评估AIMP2在肿瘤免疫中的作用，我们使用癌症基因组图谱（TCGA）、基因型-组织表达（GTEx）和癌细胞系百科全书（CCLE）数据集进行了泛癌多数据库分析，研究了表达水平、预后、肿瘤进展和免疫微环境。此外，我们使用细胞计数试剂盒8（CCK-8）检测、Transwell检测和蛋白质印迹分析研究了AIMP2对乳腺癌（BRCA）增殖和迁移的影响。

结果

我们的研究结果显示，与正常组织相比，AIMP2在24种肿瘤组织类型中过表达，且与四个肿瘤分期相关。生存分析表明，AIMP2表达与某些癌症患者的总生存期（OS）密切相关，在五种癌症类型中，AIMP2高表达与较差的预后相关。

结论

最后，siRNA介导的AIMP2敲低抑制了BRCA细胞的增殖和迁移。总之，我们的泛癌分析表明，AIMP2可能在肿瘤免疫中起关键作用，并可作为潜在的预后标志物，尤其是在BRCA中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/1f89a336de39/CG-24-307_F10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/a92712d8395e/CG-24-307_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/d045ca5662c0/CG-24-307_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/29917cb92d7f/CG-24-307_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/e53c0cc19022/CG-24-307_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/8008cc654b83/CG-24-307_F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/9763d9946765/CG-24-307_F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/dab9ca8779b1/CG-24-307_F7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/61787688af31/CG-24-307_F8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/aee6fa9a097c/CG-24-307_F9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/1f89a336de39/CG-24-307_F10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/a92712d8395e/CG-24-307_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/d045ca5662c0/CG-24-307_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/29917cb92d7f/CG-24-307_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/e53c0cc19022/CG-24-307_F4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/8008cc654b83/CG-24-307_F5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/9763d9946765/CG-24-307_F6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/dab9ca8779b1/CG-24-307_F7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/61787688af31/CG-24-307_F8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/aee6fa9a097c/CG-24-307_F9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d1f/10790333/1f89a336de39/CG-24-307_F10.jpg

相似文献

1
Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.泛癌分析确定AIMP2为乳腺癌的潜在生物标志物。
Curr Genomics. 2023 Dec 20;24(5):307-329. doi: 10.2174/0113892029255941231014142050.
2
Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.泛癌分析鉴定 CHD5 为胶质瘤的一个潜在生物标志物。
Int J Mol Sci. 2022 Jul 30;23(15):8489. doi: 10.3390/ijms23158489.
3
AIMP2-DX2 Promotes the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells.AIMP2-DX2 促进鼻咽癌细胞的增殖、迁移和侵袭。
Biomed Res Int. 2018 Apr 16;2018:9253036. doi: 10.1155/2018/9253036. eCollection 2018.
4
Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.泛癌分析揭示 DIP2B 在乳腺癌中的癌基因特征和预后价值。
BMC Cancer. 2023 Mar 31;23(1):296. doi: 10.1186/s12885-023-10751-3.
5
Pan-cancer and single-cell analysis reveals expression as a cancer prognostic biomarker.泛癌和单细胞分析揭示了[具体表达内容]作为一种癌症预后生物标志物的情况。 （注：原文中“expression”前缺少具体所指，翻译时根据语境补充了“[具体表达内容]”）
Front Genet. 2022 Dec 9;13:1009325. doi: 10.3389/fgene.2022.1009325. eCollection 2022.
6
A pan-cancer characterization of immune-related NFIL3 identifies potential predictive biomarker.免疫相关的NFIL3的泛癌特征鉴定出潜在的预测性生物标志物。
J Cancer. 2024 Jan 12;15(5):1271-1286. doi: 10.7150/jca.88765. eCollection 2024.
7
Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.鉴定SHCBP1作为一种潜在的生物标志物，涉及多种癌症的诊断、预后及肿瘤免疫微环境。
Comput Struct Biotechnol J. 2022 Jun 18;20:3106-3119. doi: 10.1016/j.csbj.2022.06.039. eCollection 2022.
8
Identification and structure of AIMP2-DX2 for therapeutic perspectives.鉴定和结构 AIMP2-DX2 的治疗视角。
BMB Rep. 2024 Jul;57(7):318-323. doi: 10.5483/BMBRep.2024-0053.
9
GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.GNPNAT1 是乳腺癌中与免疫浸润和免疫治疗结果相关的潜在生物标志物。
Front Immunol. 2023 May 5;14:1152678. doi: 10.3389/fimmu.2023.1152678. eCollection 2023.
10
Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer.微管蛋白α-1b 链被鉴定为一种泛癌的预后和免疫生物标志物，并在乳腺癌中进行了实验验证。
Sci Rep. 2024 Apr 8;14(1):8201. doi: 10.1038/s41598-024-58982-z.

引用本文的文献

1
Response to anti-angiogenic therapy is affected by AIMP protein family activity in glioblastoma and lower-grade gliomas.胶质母细胞瘤和低级别胶质瘤中，抗血管生成治疗的反应受AIMP蛋白家族活性的影响。
bioRxiv. 2025 Mar 14:2025.03.13.643116. doi: 10.1101/2025.03.13.643116.
2
MTCH2 promotes the malignant progression of ovarian cancer through the upregulation of AIMP2 expression levels, mitochondrial dysfunction and by mediating energy metabolism.MTCH2通过上调AIMP2表达水平、导致线粒体功能障碍以及介导能量代谢来促进卵巢癌的恶性进展。
Oncol Lett. 2024 Aug 12;28(4):492. doi: 10.3892/ol.2024.14625. eCollection 2024 Oct.

本文引用的文献

1
Systematic pan-cancer analysis identifies SLC35C1 as an immunological and prognostic biomarker.系统泛癌症分析确定 SLC35C1 为免疫和预后生物标志物。
Sci Rep. 2023 Apr 1;13(1):5331. doi: 10.1038/s41598-023-32375-0.
2
Multiparametric MRI and Radiomics in Prostate Cancer: A Review of the Current Literature.多参数磁共振成像与放射组学在前列腺癌中的应用：当前文献综述
Diagnostics (Basel). 2021 Oct 3;11(10):1829. doi: 10.3390/diagnostics11101829.
3
Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
系统泛癌症分析鉴定 TREM2 为一种免疫和预后生物标志物。
Front Immunol. 2021 Feb 17;12:646523. doi: 10.3389/fimmu.2021.646523. eCollection 2021.
4
Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer.单细胞分析 AIMP2 剪接变体为血液系统恶性肿瘤的药物敏感性和预后提供信息。
Commun Biol. 2020 Oct 30;3(1):630. doi: 10.1038/s42003-020-01353-x.
5
Visualizing and interpreting cancer genomics data via the Xena platform.通过Xena平台可视化和解读癌症基因组学数据。
Nat Biotechnol. 2020 Jun;38(6):675-678. doi: 10.1038/s41587-020-0546-8.
6
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.肿瘤突变负荷作为免疫治疗的生物标志物：当前数据和新兴概念。
Eur J Cancer. 2020 May;131:40-50. doi: 10.1016/j.ejca.2020.02.038. Epub 2020 Apr 9.
7
Quantitative Proteomics of the Cancer Cell Line Encyclopedia.癌症细胞系百科全书的定量蛋白质组学。
Cell. 2020 Jan 23;180(2):387-402.e16. doi: 10.1016/j.cell.2019.12.023.
8
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.肿瘤微环境中的免疫细胞：在癌症免疫治疗中的生物学功能和作用。
Cancer Lett. 2020 Feb 1;470:126-133. doi: 10.1016/j.canlet.2019.11.009. Epub 2019 Nov 12.
9
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.结直肠癌患者接受氟嘧啶和奥沙利铂辅助治疗的肿瘤突变负担与预后。
Clin Cancer Res. 2019 Oct 15;25(20):6141-6147. doi: 10.1158/1078-0432.CCR-19-1105. Epub 2019 Jul 8.
10
TISIDB: an integrated repository portal for tumor-immune system interactions.TISIDB：一个用于肿瘤-免疫系统相互作用的综合知识库门户。
Bioinformatics. 2019 Oct 15;35(20):4200-4202. doi: 10.1093/bioinformatics/btz210.